Pfizer Inc.
Pfizer Provides Full-Year 2026 Guidance and Revises 2025 Revenue Forecast
Summary
On December 16, 2025, Pfizer Inc. issued a press release announcing its full-year 2026 revenue guidance of $59.5 to $62.5 billion, with Adjusted diluted EPS expected to range between $2.80 and $3.00. Additionally, Pfizer revised its full-year 2025 revenue guidance to approximately $62.0 billion, while reaffirming all other components of its 2025 financial guidance. A detailed financial outlook and comparison with the previous guidance are available in the furnished press release.
Profitelligence Alerts
Get alerts for PFE
Be first to know when Pfizer Inc. files with the SEC.
Filing Categories
Advertisement
About Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation, recognized for its role in the research, development, and manufacturing of healthcare products. Operating in the health sector, Pfizer focuses on creating innovative medicines and vaccines that significantly improve patients' lives. It is renowned for its contributions to pivotal health areas, such as oncology, immunology, cardiovascular health, and rare diseases. Pfizer maintains a robust pipeline of products at various stages of clinical development, enhancing its market position and impact. The company is instrumental in the global pharmaceutical landscape, contributing to public health with breakthroughs like vaccines and therapies that tackle some of the world's most challenging diseases. Headquartered in New York City, Pfizer plays a critical role in addressing urgent medical needs worldwide and is involved in extensive collaborations with scientific communities and healthcare systems. As a key player in the pharmaceutical industry, Pfizer’s developments and strategic initiatives can influence market trends and health policies, underscoring its importance in the global effort to combat health issues.
Official SEC Documents
Advertisement